Checkpoint Therapeutics, Inc. financial data

Symbol
CKPT on Nasdaq
Location
95 Sawyer Road, Suite 110, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 37.2 % +69.2%
Debt-to-equity -159 % -24.2%
Return On Equity 439 % +64.2%
Return On Assets -743 % +21.8%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 53.6M shares +98.4%
Entity Public Float 69.3M USD +110%
Weighted Average Number of Shares Outstanding, Basic 39.7M shares +112%
Weighted Average Number of Shares Outstanding, Diluted 39.7M shares +112%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 41K USD +32.3%
Research and Development Expense 36.2M USD -17%
General and Administrative Expense 20.1M USD +131%
Operating Income (Loss) -56.2M USD -7.72%
Nonoperating Income (Expense) -66K USD -122%
Net Income (Loss) Attributable to Parent -56.2M USD -8.47%
Earnings Per Share, Basic -1.42 USD/shares +55.2%
Earnings Per Share, Diluted -1.42 USD/shares +55.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.6M USD +34%
Assets, Current 7.47M USD +38.9%
Assets 7.47M USD +38.9%
Accounts Payable, Current 6.09M USD -7.29%
Employee-related Liabilities, Current 1.88M USD +55.6%
Liabilities, Current 20.1M USD +9.07%
Liabilities 20.1M USD +9.07%
Retained Earnings (Accumulated Deficit) -371M USD -17.9%
Stockholders' Equity Attributable to Parent -12.6M USD +3.23%
Liabilities and Equity 7.47M USD +38.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.47M USD +53.9%
Net Cash Provided by (Used in) Financing Activities 12.8M USD +87.8%
Common Stock, Shares Authorized 175M shares +119%
Common Stock, Shares, Issued 53.6M shares +98.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.31M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.6M USD +34%
Deferred Tax Assets, Valuation Allowance 89.4M USD +2.46%
Deferred Tax Assets, Gross 89.4M USD +2.46%
Deferred Tax Assets, Operating Loss Carryforwards 51.3M USD +14%
Additional Paid in Capital 350M USD +17.6%